poisar

Stocks · News reference

Pharming to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Fiscal.ai

Pharming Group N.V. announced it will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference in London.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Globenewswire IncPharming Group N.V.

    Pharming to participate in fireside chat at Jefferies Global Healthcare Conference in London

    Pharming Group announced its participation in the 2026 Jefferies Global Healthcare Conference on November 16-19, with management presenting on November 18. The company reported strong revenue growth in Q3 2026 and highlighted the MHRA approval of Joenja® (leniolisib) as the first treatment specifically for children with APDS in the U.K., along with upcoming CVID topline data expected in November.

  2. Globenewswire IncPharming Group N.V.

    MHRA approves Pharming’s Joenja® (leniolisib) as first treatment specifically for children with APDS in the U.K.

    The U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved an extension of Pharming's Joenja® (leniolisib) to treat children aged 4 to 11 years weighing at least 27kg with activated PI3K delta syndrome (APDS), a rare primary immunodeficiency. This marks the first treatment approved in the U.K. specifically for children with APDS, with availability expected in February 2027. The approval is supported by clinical data from Pharming's pediatric clinical program.

  3. The Motley FoolThe Motley Fool Team

    Pharming: 3 Key Takeaways for Long-Term Investors

    Pharming reported Q3 2026 revenue growth of 21% to $117.6 million with operating profit surging 89% to $29.9 million. The company's core rare disease product RUCONEST stabilized demand, while Joenja accelerated 58% growth through geographic and pediatric expansion. Management is advancing its clinical pipeline into larger immunodeficiency markets with $191 million in cash and no need for external financing.